Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilhelm Huisinga

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Critical Care (London, England)|October 24, 2017
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational studyLisa Ehmann, Michael Zoller, Iris K Minichmayr, et al.
European Journal of Endocrinology|October 26, 2020
Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'Robin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
European Journal of Clinical Pharmacology|November 9, 2020
Therapeutic drug monitoring of oral targeted antineoplastic drugsAnna Mueller-Schoell, Stefanie L Groenland, Oliver Scherf-Clavel, et al.
Antibiotics (Basel, Switzerland)|April 30, 2021
Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill PatientsUwe Liebchen, Marian Klose, Michael Paal, et al.
Pharmaceuticals (Basel, Switzerland)|March 29, 2023
Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia PatientsViktoria Stachanow, Uta Neumann, Oliver Blankenstein, et al.
Infection|April 25, 2025
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational studyFranz Weber, Christina Scharf, Linda B S Aulin, et al.
Antibiotics (Basel, Switzerland)|June 24, 2022
Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision ToolsFerdinand Anton Weinelt, Miriam Songa Stegemann, Anja Theloe, et al.
United European Gastroenterology Journal|October 20, 2020
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel diseaseAna-Marija Grišić, Maria Dorn-Rasmussen, Bella Ungar, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trialAnna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Clinical Pharmacology and Therapeutics|June 25, 2020
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation ApproachAnna Mueller-Schoell, Lena Klopp-Schulze, Werner Schroth, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Critical Care (London, England)|October 24, 2017
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational studyLisa Ehmann, Michael Zoller, Iris K Minichmayr, et al.
European Journal of Endocrinology|October 26, 2020
Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'Robin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
European Journal of Clinical Pharmacology|November 9, 2020
Therapeutic drug monitoring of oral targeted antineoplastic drugsAnna Mueller-Schoell, Stefanie L Groenland, Oliver Scherf-Clavel, et al.
Antibiotics (Basel, Switzerland)|April 30, 2021
Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill PatientsUwe Liebchen, Marian Klose, Michael Paal, et al.
Pharmaceuticals (Basel, Switzerland)|March 29, 2023
Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia PatientsViktoria Stachanow, Uta Neumann, Oliver Blankenstein, et al.
Infection|April 25, 2025
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational studyFranz Weber, Christina Scharf, Linda B S Aulin, et al.
Antibiotics (Basel, Switzerland)|June 24, 2022
Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision ToolsFerdinand Anton Weinelt, Miriam Songa Stegemann, Anja Theloe, et al.
United European Gastroenterology Journal|October 20, 2020
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel diseaseAna-Marija Grišić, Maria Dorn-Rasmussen, Bella Ungar, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trialAnna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Clinical Pharmacology and Therapeutics|June 25, 2020
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation ApproachAnna Mueller-Schoell, Lena Klopp-Schulze, Werner Schroth, et al.
Pageof 9